Please assess the completion status of the following clinical trial:

Trial Title: Medical Therapy of Prostatic Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Peak urinary flow rate at least 4 ml/sec but not greater than 15 ml/sec; and voided volume is at least 125 ml.~* American Urological Association Symptom Score is greater than or equal to 8 and less than or equal to 30.~* Voluntarily signed the informed consent agreement prior to the performance of any study procedures.~Exclusion Criteria:~* Serum prostate specific antigen level greater than 10 ng/ml.~* Supine blood pressure less than 90/70 mmHG. Orthostatic hypotension.~* Any prior medical or surgical intervention for BPH.~* Received any prior experimental intervention (either medical or surgical) for prostate disease or enrolled in any other study protocol.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Doxazosin and Finasteride placebos
- Doxazosin (Type: EXPERIMENTAL): Doxazosin and Finasteride placebo
- Finasteride (Type: EXPERIMENTAL): Doxazosin placebo and Finasteride
- Combination (Type: EXPERIMENTAL): Doxazosin and Finasteride

Based on this trial design, predict the completion outcome and termination type (if applicable).